Search for other papers by Luigia Cinque in
Google Scholar
PubMed
Search for other papers by Angelo Sparaneo in
Google Scholar
PubMed
Search for other papers by Antonio S Salcuni in
Google Scholar
PubMed
Search for other papers by Danilo de Martino in
Google Scholar
PubMed
Search for other papers by Claudia Battista in
Google Scholar
PubMed
Search for other papers by Francesco Logoluso in
Google Scholar
PubMed
Search for other papers by Orazio Palumbo in
Google Scholar
PubMed
Search for other papers by Roberto Cocchi in
Google Scholar
PubMed
Search for other papers by Evaristo Maiello in
Google Scholar
PubMed
Search for other papers by Paolo Graziano in
Google Scholar
PubMed
Search for other papers by Geoffrey N Hendy in
Google Scholar
PubMed
Search for other papers by David E C Cole in
Google Scholar
PubMed
Search for other papers by Alfredo Scillitani in
Google Scholar
PubMed
Search for other papers by Vito Guarnieri in
Google Scholar
PubMed
/mL. IHC, immunohistochemistry; NA, not available; neg, negative; NP, Not Performed/Not Applicable; PHPT, primary hyperparathyroidism; PNET, pancreatic neuroendocrine tumor; pos, positive; PTH, parathyroid hormone. After the identification of the
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan, USA
Veterans Affairs Medical Center, Ann Arbor, Michigan, USA
Search for other papers by Richard J Auchus in
Google Scholar
PubMed
obtained with thyroxine therapy for severe hypothyroidism, estrogen for ovarian failure, growth hormone for pituitary dwarfism, and most recently, recombinant parathyroid hormone for hypoparathyroidism ( 2 ). These sweeping responses to properly
Search for other papers by Elena Pardi in
Google Scholar
PubMed
Search for other papers by Stefano Mariotti in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Katiuscia Benfini in
Google Scholar
PubMed
Search for other papers by Simona Borsari in
Google Scholar
PubMed
Search for other papers by Federica Saponaro in
Google Scholar
PubMed
Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed
Search for other papers by Antonello Cappai in
Google Scholar
PubMed
Search for other papers by Chiara Satta in
Google Scholar
PubMed
Search for other papers by Marco Mastinu in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Filomena Cetani in
Google Scholar
PubMed
details of the index case are briefly reported. Primary hyperparathyroidism (PHPT) was firstly diagnosed in the index case, a 41-year-old woman (serum calcium 11.65 mg/dl (8.4–10.2 mg/dl) and parathyroid hormone (PTH) 189 pg/ml (10–65 pg/ml)). In the same
Search for other papers by Daniel Bell in
Google Scholar
PubMed
Search for other papers by Julia Hale in
Google Scholar
PubMed
Search for other papers by Cara Go in
Google Scholar
PubMed
Search for other papers by Ben G Challis in
Google Scholar
PubMed
Search for other papers by Tilak Das in
Google Scholar
PubMed
Search for other papers by Brian Fish in
Google Scholar
PubMed
Department of Medical Genetics, Cambridge University, Cambridge, UK
Search for other papers by Ruth T Casey in
Google Scholar
PubMed
Introduction Primary hyperparathyroidism (pHPT) is a common endocrine disorder with a prevalence of 1–4 per 1000 and a 3 to 1 female to male ratio ( 1 ). It is characterised by inappropriate and excessive secretion of parathyroid hormone (PTH
Search for other papers by Sondra O’Callaghan in
Google Scholar
PubMed
Search for other papers by Hanford Yau in
Google Scholar
PubMed
about 3 months after the onset of hypercalcemia ( 7 ). Median survival in patients with squamous cell carcinoma and hypercalcemia was 17–64 days ( 8 , 9 ). In a series of patients with parathyroid hormone-related peptide (PTH-RP) mediated hypercalcemia
Search for other papers by Qian Wang in
Google Scholar
PubMed
Search for other papers by Jiacheng Wang in
Google Scholar
PubMed
Search for other papers by Yunhui Xin in
Google Scholar
PubMed
Search for other papers by Ziyang He in
Google Scholar
PubMed
Search for other papers by Xiang Zhou in
Google Scholar
PubMed
Search for other papers by Xing Liu in
Google Scholar
PubMed
Search for other papers by Teng Zhao in
Google Scholar
PubMed
Search for other papers by Lihan He in
Google Scholar
PubMed
Search for other papers by Hong Shen in
Google Scholar
PubMed
Search for other papers by Mulan Jin in
Google Scholar
PubMed
Search for other papers by Bojun Wei in
Google Scholar
PubMed
repeated surgical resections and have poor prognosis; most die of uncontrollable hypercalcemia due to excessive parathyroid hormone (PTH) secretion ( 5 ), with 5- and 10-year survival rates between 77–91% and 49–77%, respectively ( 1 , 5 , 8 , 9 , 10
Search for other papers by A Chinoy in
Google Scholar
PubMed
Search for other papers by M Skae in
Google Scholar
PubMed
Search for other papers by A Babiker in
Google Scholar
PubMed
Search for other papers by D Kendall in
Google Scholar
PubMed
Search for other papers by M Z Mughal in
Google Scholar
PubMed
Search for other papers by R Padidela in
Google Scholar
PubMed
Introduction Hypoparathyroidism (HPT) is the partial or complete reduction of parathyroid hormone (PTH) secretion from the parathyroid glands. PTH stimulates 1-alpha-hydroxylase enzyme to produce 1,25(OH) 2 -vitamin D, which facilitates active
Search for other papers by Anna Eremkina in
Google Scholar
PubMed
Search for other papers by Julia Krupinova in
Google Scholar
PubMed
Search for other papers by Ekaterina Dobreva in
Google Scholar
PubMed
Search for other papers by Anna Gorbacheva in
Google Scholar
PubMed
Search for other papers by Ekaterina Bibik in
Google Scholar
PubMed
Search for other papers by Margarita Samsonova in
Google Scholar
PubMed
Search for other papers by Alina Ajnetdinova in
Google Scholar
PubMed
Search for other papers by Natalya Mokrysheva in
Google Scholar
PubMed
). Parathyroidectomy is the only cure for severe hypercalcemia, or HC caused by PHPT. Removing the parathyroid tumor significantly lowers the levels of parathyroid hormone (PTH) in blood, and thereby decreases serum calcium ( 5 ). However, immediate treatment for
Search for other papers by Cheng Han Ng in
Google Scholar
PubMed
Search for other papers by Yip Han Chin in
Google Scholar
PubMed
Search for other papers by Marcus Hon Qin Tan in
Google Scholar
PubMed
Search for other papers by Jun Xuan Ng in
Google Scholar
PubMed
Department of Medicine, National University Hospital, Singapore
Search for other papers by Samantha Peiling Yang in
Google Scholar
PubMed
Search for other papers by Jolene Jiayu Kiew in
Google Scholar
PubMed
Department of Medicine, National University Hospital, Singapore
Search for other papers by Chin Meng Khoo in
Google Scholar
PubMed
Introduction Primary hyperparathyroidism (PHPT) is a common endocrine disorder that is caused by excessive or inappropriate parathyroid hormone (PTH) secretion with simultaneous derangement of both phosphate and calcium metabolism. PHPT is
Search for other papers by Jeremy Turner in
Google Scholar
PubMed
Search for other papers by Neil Gittoes in
Google Scholar
PubMed
Search for other papers by Peter Selby in
Google Scholar
PubMed
Search for other papers by the Society for Endocrinology Clinical Committee in
Google Scholar
PubMed
magnesaemia) Cytotoxic drug-induced hypocalcaemia Pancreatitis, rhabdomyolysis and large volume blood transfusions Investigations Serum calcium (adjusted for albumin) Phosphate Parathyroid hormone (PTH) Urea and electrolytes Vitamin D Magnesium